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Background: Schizophrenia is associated with a lowered life expectancy due to cardiovascular disease. This is, at
least in part, related to an increased vulnerability to the development of metabolic syndrome (MetS) in patients
with schizophrenia. The dysregulation of apolipoproteins (Apos) may also play a role in the pathogenesis of
schizophrenia via their effect on cerebral cholesterol processing.
Aim: The aim of this study was to investigate serum Apos A1, C3, E, A2 and C2 concentration in schizophrenia
patients with or without MetS in comparison to healthy donors.
Methods: After obtaining informed consent, 53 patients with a diagnosis of paranoid schizophrenia according to
ICD-10 criteria (F20) were included. Patients were divided into two groups with (N ¼ 26) and without (N ¼ 27)
MetS according to the criteria of the International Diabetes Federation. The control group included 20 mentally
and physically healthy subjects. Serum Apos A1, A2, C2, C3 and E were measured using xMAP technology
(Luminex).
Results: Serum ApoA1 was signiﬁcantly decreased in patients with schizophrenia compared to healthy subjects (p
¼ 0.002); ApoA2 was lower in patients without MetS in comparison to patients with MetS (p ¼ 0.017) and the
levels of ApoC3 and ApoC2 were increased in patients with schizophrenia with MetS in comparison with the
control group and also with patients without MetS. No other signiﬁcant differences were established concerning
the other assayed apolipoproteins.
Conclusions: In line with literature data the results of our study suggest that while disturbances in ApoA1 level may
play a role in the pathogenesis of schizophrenia, ApoA2, ApoC2, ApoC3 and ApoE may be primarily related to
metabolic imbalance.1. Introduction
Schizophrenia is, without doubt, one of the most important severe
mental illnesses (SMIes), and with a median life time prevalence of 6.35
per 1000 persons (25% quartile: 4.10; 75% quartile: 8.72) is among the
top 15 leading causes of disability worldwide [1]. Considering 11 studies
including 302,691 patients from all inhabitant continents (except for
South America) the average for years of potential life lost amounted to
14.5 (95% CI 11.2–17.8) and the average life expectancy was 64.7 yearsnen).
m 5 May 2019; Accepted 28 Jun
vier Ltd. This is an open access ar(95% CI 61.1–68.3) [2]. Cardiovascular diseases form a major contrib-
utor to the excess of mortality in patients with schizophrenia; a
meta-analysis of 13 studies involving over 3.5 million participants found
a pooled relative risk for the incidence of cardiovascular disease of 1.53
(CI95% 1.27–1.86) for schizophrenia in comparison with the reference
group [3]. Metabolic syndrome (MetS) is generally considered to be a
major predictor of cardiovascular disease [4]. In the general population,
a diagnosis of MetS has a relative risk of 2-fold for cardiovascular disease
over 5–10 years and at least a 5-fold risk for type 2 diabetes [4]. Ine 2019
ticle under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-
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30.1%–35.0%); there were only minor differences according to treatment
setting (inpatient vs outpatient) and by country of origin; there were no
appreciable difference between males and females [5]. Older age, and
particularly illness durations, had a strong inﬂuence on the prevalence of
MetS [5]. This can be related to the usage of psychotropic drugs such as
clozapine and second generation antipsychotics. In drug-naïve patients
with schizophrenia and related disorders the MetS rate is about 10% [6,
7], while this was found to be about 52% in patients using clozapine [5].
The usage of other antipsychotics is also associated with an increased risk
of MetS [5, 8, 9, 10]. Olanzapine appears to have the highest rate of risk,
and aripiprazole the lowest [10]. This may correspond to the observed
association between their use and type 2 diabetes mellitus in
population-based studies [9]. Dyslipidemia (a decreased high density
lipoprotein (HDL)-cholesterol and elevated triglycerides), is a major
component of MetS [4], which is commonly seen in patients with
schizophrenia [5]. Treatment with antipsychotics is associated with these
lipid abnormalities and an increased risk of diabetes [6, 11]. In addition,
over 20% of the treatment-naïve schizophrenia patients and ﬁrst-episode
patients have a lowered HDL-cholesterol level and a glucose dysregula-
tion/insulin resistance [6, 12]. This percentage corresponds to the ﬁgure
of 144 un-medicated and antipsychotic-naïve German patients with ﬁrst
episode psychosis (20.2%; 95% CI 13.5%–28.3%), which was higher
than in 3995 control persons (13.3%; 95% CI 12.2%–14.4%). It is highly
likely, therefore, that the high rate of cardiovascular disorder in patients
with schizophrenia is partly associated to a disease-related dyslipidemia
which also increases their vulnerability to the effects of treatment with
certain antipsychotics. Finding a biomarker which can predict this
increased vulnerability could be an important facilitator in selecting the
best treatment for these patients.
Cholesterol has an essential role in determining the structure and
function of the neuronal system of the brain [13]. Due to its incapacity to
pass through the blood-brain barrier, all cerebral cholesterol is synthe-
tized locally by glia cells; this also makes recycling of neuronal choles-
terol of critical importance [13]. Apolipoproteins (Apos) have an
essential role for lipid transport, peripherally by being the protein
component of lipoproteins, but probably also within the central nervous
system (CNS). Some of these proteins, such as ApoE (which is found in all
plasma lipoproteins), are synthetized mainly within the brain, while
others, such as ApoA1 is synthetized peripherally and crosses the
blood-brain barrier [13]. The potential role of Apos in both dyslipidemia
and cerebral neuronal functioning in schizophrenia make these proteins
good candidates for the study of their potential as MetS biomarkers in
patients with this disorder.
The major apolipoproteins include ApoE, ApoB, ApoA1, ApoA2,
ApoA4, ApoC1, ApoC2, and ApoC3 [14]. ApoA1 is the most important
protein component of HDL particles in plasma. This protein, as a
component of HDL particles, enables efﬂux of fat molecules by accepting
fats from within cells for transport. ApoA1 is often used as a biomarker
for the prediction of cardiovascular diseases. ApoA2 is the second most
abundant protein of the high density lipoprotein particles and appears to
be a key regulatory factor of HDL metabolism [15]. ApoC2 is a small
exchangeable apolipoprotein found on triglyceride-rich lipoprotein par-
ticles, such as chylomicrons and very low-density lipoproteins (VLDL), as
well as on HDL, particularly during fasting. ApoC2 plays a critical role in
triglyceride-rich lipoprotein metabolism by acting as a cofactor of lipo-
protein lipase; this is the main enzyme which hydrolyses these tri-
glycerides [16]. ApoC3 also has a critical role in the metabolism of
triglyceride-rich lipoproteins; there is evidence supporting this apolipo-
protein as an emerging target for hypertriglyceridemia and associated
cardiovascular disorders [17]. ApoE is a fat-binding protein that is part of
the chylomicron and intermediate-density lipoprotein (IDL) and are
essential for the normal processing (catabolism) of triglyceride-rich li-
poproteins. In peripheral tissues, ApoE is produced primarily by the liver
and macrophages and mediates cholesterol metabolism. In the central
nervous system, ApoE is mainly produced by astrocytes and transports2cholesterol to neurons via ApoE receptors which are members of the low
density lipoprotein receptor gene family. ApoE is the principal choles-
terol carrier in the brain [18]. In humans, ApoE exists in three different
isoforms: ε2, ε3 and ε4. ApoE ε3 is the most common isoform, while the
ε4 isoform confers the greatest genetic risk for Alzheimer's disease. The
mechanisms underlying exactly how ApoE contributes to the pathogen-
esis of this disease, however, are still being debated [19].
The aim of our study is to investigate serum apolipoprotein A1, A2,
C2, C3, and E concentration in schizophrenia patients with or without
metabolic syndrome and to compare these levels with those of healthy
donors.
2. Materials & methods
2.1. Patients
This study was carried out in accordance with the Code of Ethics of
the World Medical Association (Declaration of Helsinki 1975, revised in
Fortaleza, Brazil, 2013), established for experiments involving humans.
We recruited patients from the Mental Health Research Institute Inpa-
tient Department and Psychiatric Hospital located in Tomsk, Tomsk
oblast (region) of Siberia, Russia. Recruitment started after the study was
approved (protocol N187, 24.04.2018) by the Local Bioethics Committee
of the Mental Health Research Institute. Each patient provided written
informed consent after a proper explanation was given. The inclusion
criteria were a clinical diagnosis of schizophrenia, according to the In-
ternational Statistical Classiﬁcation of Diseases and Related Health
Problems, 10th Revision (ICD-10: F20) and an age of between 18 and 65.
Symptom severity was measured with the Positive and Negative Syn-
drome Scale [20] at the beginning of the observation. Most patients
received antipsychotic drugs in anti-relapse and maintenance dosages
before admission to the clinic. They were often noncompliant, and were
hospitalized in the clinic due to the exacerbation of schizophrenic
symptoms.
Patients were divided into two groups, either with or without MetS,
according to the criteria of the International Diabetes Federation IDF [4,
21]. According to these criteria, the metabolic syndrome is diagnosed in a
patient with central obesity (waist circumference more than 94 cm in
men, more than 80 cm in women) and the presence of any two of the
following four signs:
 The concentration of triglycerides in serum is higher than 1.7 mmol/L
(150 mg/dL), or lipid-lowering therapy is carried out.
 The concentration of high-density lipoprotein in serum is below 1.03
mmol/L (40 mg/dL) in men and 1.29 mmol/L (50 mg/dL) in women.
 The arterial blood pressure level is systolic above 130 mmHg or
diastolic above 85 mmHg (or with treatment of previously diagnosed
hypertension).
 Serum glucose concentration is greater than 5.6 mmol/L (100mg/dL)
(or previously diagnosed type 2 diabetes).
2.2. Control group
The control group consisted of persons who were recruited from a
group of blood donors, hospital staff members, and students, on a
voluntary basis. They reported on questioning to be mentally and so-
matically healthy individuals.
2.3. Blood sampling
Laboratory examination was conducted during the ﬁrst days of hos-
pitalization. Blood samples were drawn after an 8-h overnight fast into
tubes with a clot activator (CAT) to isolate the serum (BD Vacutainer).
Blood samples with CAT were centrifuged for 30 min at 2000g at 4 C
to isolate the serum; the serum was stored at 20 C (or – 80 C) until
analysis.
Table 2
Concentration of apolipoproteins (μg/dL) in the serum of patients with schizo-
phrenia and healthy individuals (Me [Q1; Q3]).
Healthy persons N ¼
25













43.47 [28.26; 68.26] 0.443
ApoC2, μg/
dL
13.75 [10.89; 25.36] 20.17 [9.43; 36.3] 0.268
ApoC3, μg/
dL
31.66 [23.16; 41.49] 42.55 [20.865; 67.59] 0.216
ApoE, μg/dL 4.655 [3.21; 6.12] 4.6 [3.59; 5.87] 0.911
Abbreviations: ApoA1, ApoA2, ApoC2, ApoC3, ApoE – apolipoproteins A1, A2,
C2, C3, E.Comparisons between groups were performed using Mann-Whitney U-
test. * - p < 0.05 – statistically signiﬁcant difference (highlighted in bold).
Table 3
Concentration of apolipoproteins (μg/dL) in the serum of patients with metabolic






ApoA1, μg/dL 55.23 [41; 73.75] 49.41 [37.12; 58.82] 0.266
ApoA2, μg/dL 37.9 [22.96; 60.51] 63.67 [32.6; 75.81] 0.017*
ApoC2, μg/dL 12.56 [7.22; 20.95] 32.4 [19.955; 49.06] <0.001*
ApoC3, μg/dL 24.035 [10.585; 44.34] 59.86 [39.205; 95.13] <0.001*
ApoE, μg/dL 4.36 [2.41; 5.33] 5.03 [4.05; 6.03] 0.075
Abbreviations: MetS – metabolic syndrome; ApoA1, ApoA2, ApoC2, ApoC3,
ApoE – apolipoproteins A1, A2, C2, C3, E.Comparisons between groups were
performed using Mann-Whitney U-test. * – p < 0.05 – statistically signiﬁcant
difference (highlighted in bold).
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Concentrations of Apos were determined on the MAGPIX multiplex
analyzer (Luminex, USA) using xMAP® Technology. To determine the
levels of ﬁve markers (АpoА1, АpoА2, АpoС2, АpoС3, ApoE) the stan-
dard panel APOMAG-62K by MILLIPLEX® MAP (Merck, Darmstadt,
Germany) was used. System MILLIPLEX® MAP includes antibodies spe-
ciﬁc binding with the tests and conjugated with bits xMAP® using the
minimum volume of the sample (25 μl). Magnetic bits are added to the
test sample then biotinylated detectable antibodies are introduced into
the reaction mixture. To complete the reaction, incubation with strep-
tavidin peroxidase conjugate is carried out on each microsphere. Each
individual microsphere is identiﬁed in a multiplex analyzer and the result
of its biological analysis is quantiﬁed on the basis of ﬂuorescent signals.
The detected information is processed by specialist software (Lumi-
nexxPONENT®) with the subsequent export of data to program the
MILLIPLEX® Analyst 5.1. Final results on serum apolipoprotein con-
centrations are presented in mg/dL.
2.5. Statistics
Statistical analyses were performed using the SPSS software for
Windows, version 20.0. The data were tested for the normality of the
distribution by the Shapiro-Wilk test. Between-group differences were
evaluated using the Mann-Whitney U-test for independent samples with
non-normal distribution. Results were expressed as median with 25%-
and 75%-quartiles (Me [Q1; Q3]). P-values less than 0.05 were consid-
ered as signiﬁcant.
3. Results
We included 53 patients with a diagnosis of paranoid schizophrenia
and 25 healthy subjects (Table 1); all patients received antipsychotic
treatment in anti-relapse and maintenance dosages before admission to
the clinic. All patients were prescribed conventional and atypical anti-
psychotics for at least 6 weeks, 11 of them (20.8%) used haloperidol, 19
(35.8%) risperidone, 12 (22.6%) olanzapine, and 11 (20.8%) quetiapine.
According to IDF-criteria, 26 patients had MetS and 27 patients were
without it.
We found a signiﬁcant decrease in the concentration of ApoA1 in the
serum of patients with schizophrenia in comparison to healthy subjects (p
¼ 0.002) (Table 2). ApoA2 was signiﬁcantly decreased in patients
without MetS in comparison to patients with MetS (p ¼ 0.017) (Table 3).
Analysis of the levels of other Apos revealed a signiﬁcant increase of
ApoC3 in patients with MetS in comparison to the controls (p ¼ 0.001)
and patients without MetS (p < 0.001). A similar situation was observed
with respect to ApoC2: patients with MetS had signiﬁcantly higher levels
than the healthy subjects (p ¼ 0.002) and those patients without MetS (p
< 0.001). A signiﬁcant increase in the level of ApoE was found in patients
with MetS (p ¼ 0.001), while at the ﬁrst point of the study differences inTable 1




schizophrenia N ¼ 53
p-
value
Age, Me [Q1; Q3] 31 [28; 41] 35 [25.5; 42.5] 0.410
years (Min – Max) (19–57) (22–68)
Male, n (%) 14 (56%) 27 (51%) 0.109
Female, n (%) 11 (44%) 26 (49%)
Duration of disease, Me
[Q1; Q3] years
N/A 13.5 [4; 20.8]
BMI, Me [Q1; Q3] value 26.4 [22.4;
31.45]
27 [23.1; 32.1] 0.2946
PANSS, Me [Q1; Q3]
total score
N/A 102 [92; 109]
Comparisons between groups were performed using χ2 test for sex and Mann-
Whitney U-test for age. N/A, not applicable.
3the groups were at the level of statistical trends. No other signiﬁcant
differences were established concerning the other assayed
apolipoproteins.
4. Discussion
Of particular importance may be our ﬁnding that serum ApoA1 is
signiﬁcantly lower in patients with schizophrenia in comparison to
healthy blood donors, but that the levels barely differ between patients
with and without MetS. ApoA1 is the major protein component of HDL
[15, 22]; it is believed to be synthetized peripherally and to enter the
brain by crossing the blood-brain barrier [13]. Concerning the lowered
levels in schizophrenia, our results correspond to literature data [23, 24,
25, 26, 27]. Previous studies have, as far as we know, never discriminated
between patients with and without MetS. All our patients with schizo-
phrenia were using antipsychotics and had already been ill for a
considerable number of years: this suggests that ApoA1 is primarily
associated with a component of the schizophrenic disease process and
therefore not with the likelihood of antipsychotic drug-induced MetS.
Venkatasubramanian et al. have observed that serum HDL has a signiﬁ-
cant inverse correlation with negative symptoms in 60 anti-
psychotic-naïve patients with schizophrenia [28]. The mechanism
involved is entirely unknown. Lowered levels of ApoA1may play a role in
the pathogenesis of multiple sclerosis because ApoA1 acts as an
anti-inﬂammatory factor [29, 30]. Inﬂammation also plays a major role
in the pathophysiology of schizophrenia [31, 32]. Study of the interac-
tion between ApoA1, other anti-inﬂammatory mediators and
pro-inﬂammatory cytokines in the pathogenesis of schizophrenia and
MetS deﬁnitely deserve priority.
ApoA2 is the second most abundant protein in HDL, accounting for
approximately 20% of total HDL protein [33, 34]. Similarly to ApoA1, it
has potent anti-inﬂammatory effects [33], although high serum ApoA2
A.S. Boiko et al. Heliyon 5 (2019) 1–5predicted MetS compared with low ApoA2 concentrations in an elderly
Turkish population [34]. This corresponds to our ﬁndings, and as a
matter of fact would indicate pro-inﬂammatory instead of
anti-inﬂammatory effects [34]. This ﬁnding is not very surprising, as
ApoA1 and ApoE are also known to have both pro- and anti-inﬂammatory
effects depending on particular circumstances [35, 36, 37].
In our study, patients with MetS were found to have signiﬁcantly
higher serum ApoC2 and ApoC3 levels than those without MetS. The
human ApoCs are found within chylomicrons (very low density lipo-
protein, VLDL) and HDL and appear to play a complex role in the pro-
cessing of triglycerides [38]. Our results correspond to those of Savinova
et al. who compared 60 MetS subjects with a sample of 14 age- and
sex-matched control subjects and found that total plasma - apoA1 was
lower in metabolic syndrome patients in comparison with the healthy
controls [39]. Song et al. observed that ApoC3 in particular correlated
positively with coronary atherosclerosis (n ¼ 224 with vs. 177 without)
[40].
4.1. Strengths and limitations
To our knowledge this is the ﬁrst paper in which patients with
schizophrenia and with or without MetS are compared with healthy
controls. As far as is comparable, our results largely correspond to what is
found in the literature. The limitations are that we studied a rather
restricted number of individuals, who were not characterized/analyzed
with respect to the separate components of MetS, alcohol intake and
current drug treatment (antipsychotics, lipid-lowering drugs,
antidiabetics).
4.2. Conclusions
Our results suggest that disturbances in the level of Apo A1 play a role
in the pathogenesis of schizophrenia as well as MetS, while the level of
ApoC3 and ApoC2 can reﬂect the metabolic dis-balance and could be a
novel biomarker to predict metabolic side effects associated with anti-
psychotic treatment. Future studies with a larger sample size, a well-
deﬁned control group and a longer study time duration could be of
great clinical utility, particularly if these can predict antipsychotic-
associated metabolic problems in patients who carry a higher cardio-
vascular risk. A correlation of serum or CSF ApoA1 levels with those of
other pro- and anti-inﬂammatory mediators (considering speciﬁc clinical
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